Literature DB >> 14641615

Invasive fungal infections are responsible for one-fifth of the infectious deaths in children with ALL.

L Grigull1, R Beier, A Schrauder, P Kirschner, L Loening, T Jack, K Welte, K W Sykora, M Schrappe.   

Abstract

The following report will discuss in detail all lethal invasive fungal infections (IFI) that occurred in a group of 2021 children with acute lymphoblasic leukaemia (ALL). The German ALL-Berlin-Frankfurt-Muenster (BFM) study group is one of the largest cooperation for the treatment of childhood ALL. Between 1995 and 2000, 2021 children with ALL received chemotherapy according to the German BFM 95 protocols (ALL-BFM 95). This population was retrospectively screened, whether a lethal fungal infection occurred: totally, in this group, 43 of 2021 (2.1%) children died because of infections. Nine of 43 (21%) patients died in the context of an IFI: six fatal Aspergillus infections and three fatal yeast infections were reported. The following report will focus on the nine children with ALL who died from IFI. The underlying risk factors (RF) included neutropenia (seven of nine patients) and steroid medication (nine of nine patients). Seven of nine children had additional medical complications (e.g. liver failure, haemolytic uraemic syndrome and acute renal failure). In six of nine children the fungal infection was progressive despite intravenous antimycotic therapy, three patients received no antifungal therapy, as IFI was not considered. The progression of IFI despite antimycotic therapy illustrates the inherent problems of diagnosis and the need for innovative therapeutic modalities. The high percentage (21%) of death from IFI among lethal infections in paediatric ALL patients illustrates the relevance of fungi in this group of patients. On the contrary, the total number of IFI in paediatric ALL patients remains to be determined, as only lethal infections were included in this report.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14641615     DOI: 10.1046/j.0933-7407.2003.00931.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  6 in total

1.  Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child.

Authors:  Nicole Ritz; Roland A Ammann; Carmen Casaulta Aebischer; Mathias Gugger; Katia Jaton; Ralph A Schmid; Christoph Aebi
Journal:  Eur J Pediatr       Date:  2005-01-05       Impact factor: 3.183

2.  Small molecule microarrays of RNA-focused peptoids help identify inhibitors of a pathogenic group I intron.

Authors:  Lucas P Labuda; Alexei Pushechnikov; Matthew D Disney
Journal:  ACS Chem Biol       Date:  2009-04-17       Impact factor: 5.100

3.  Application of a standardized screening protocol for diagnosis of invasive mold infections in children with hematologic malignancies.

Authors:  Shannon M Cohn; Hanumantha R Pokala; Jane D Siegel; John E McClay; David Leonard; Jeannie Kwon; Charles F Timmons; Naomi J Winick
Journal:  Support Care Cancer       Date:  2016-08-12       Impact factor: 3.603

4.  [Requirements for hygiene in the medical care of immunocompromised patients. Recommendations from the Committee for Hospital Hygiene and Infection Prevention at the Robert Koch Institute (RKI)].

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2010-04       Impact factor: 1.513

5.  Management of Invasive Fungal Infections in Pediatric Acute Leukemia and the Appropriate Time for Restarting Chemotherapy.

Authors:  Özlem Tüfekçi; Şebnem Yılmaz Bengoa; Fatma Demir Yenigürbüz; Erdem Şimşek; Tuba Hilkay Karapınar; Gülersu İrken; Hale Ören
Journal:  Turk J Haematol       Date:  2015-04-27       Impact factor: 1.831

6.  Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control study.

Authors:  Ekaterini Kidas; Anja Möricke; Rita Beier; Karl Welte; Martin Schrappe; Martin Stanulla; Lorenz Grigull
Journal:  Int J Hematol       Date:  2009-04-08       Impact factor: 2.490

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.